Licensing deal with Boehringer Ingelheim for tumor-specific antibodies.

Find out out more here!

EDDC licenses out Pan-Coronavirus inhibitors to Everest Medicines for further development

Learn more about it here!

(edited) EDDCxNTU TB drug candidate_1030x450

EDDC x NTU collaboration against drug-resistant Tuberculosis

Read more on our joint effort against drug-resistant Tuberculosis here.

Ligature banner_draft4-2 1030x450

Ligature Therapeutics

----------Taking our innovation from Lab to Market ---------- EDDC's first spin-off

TTC banner_draft4 1030x450

Target Translation Consortium

Click to find out more!

EDDC’s inaugural Annual Report for 2021 is now ready!

Click here to learn more about EDDC’s undertakings and successes for the Year 2021.

Find out how EARO can help you in your drug discovery journey!

Click to visit the new website.


Chromos Pano Shot_ii

The Experimental Drug Development Centre (EDDC) is Singapore’s national platform for drug discovery and development, formed from the integration of the Experimental Therapeutics Centre (ETC), Drug, Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC) in 2019.

EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. We work collaboratively with public sector and industry partners to translate the great science arising from Singapore’s biomedical and clinical sciences R&D into innovative healthcare solutions, with a focus on Asian-prevalent diseases. 

EDDC possesses a full range of capabilities for the discovery and development of small molecule or antibody-based drugs and companion diagnostics. We are keen to engage with academic, clinical, and bio-pharmaceutical industry partners for development and commercialization of innovative assets and platforms. We want to jointly bring forward medicines that improve healthcare, and generate a return to support Singapore’s future drug discovery research.